YMTX vs. ADIL, LIXT, ENVB, OGEN, KTRA, HILS, XBIO, KA, AIMD, and HOTH
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Adial Pharmaceuticals (ADIL), Lixte Biotechnology (LIXT), Enveric Biosciences (ENVB), Oragenics (OGEN), Kintara Therapeutics (KTRA), Hillstream BioPharma (HILS), Xenetic Biosciences (XBIO), Kineta (KA), Ainos (AIMD), and Hoth Therapeutics (HOTH). These companies are all part of the "pharmaceutical preparations" industry.
Yumanity Therapeutics (NASDAQ:YMTX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
Adial Pharmaceuticals has a net margin of 0.00% compared to Yumanity Therapeutics' net margin of -660.61%. Adial Pharmaceuticals' return on equity of -250.52% beat Yumanity Therapeutics' return on equity.
25.1% of Yumanity Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 12.5% of Yumanity Therapeutics shares are held by insiders. Comparatively, 14.5% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Yumanity Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
Adial Pharmaceuticals has lower revenue, but higher earnings than Yumanity Therapeutics. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Adial Pharmaceuticals had 5 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 6 mentions for Adial Pharmaceuticals and 1 mentions for Yumanity Therapeutics. Adial Pharmaceuticals' average media sentiment score of 0.33 beat Yumanity Therapeutics' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.
Adial Pharmaceuticals received 94 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote.
Summary
Adial Pharmaceuticals beats Yumanity Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
